Updates from the 2022 American Society of Hematology Annual Meeting
The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 300 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific Advisory Board (SAB) and grantees, contributing to an abstract presented at the conference.
Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provides a critical forum for leading hematologists/oncologists to present their findings to over 20,000 of their peers. Among the distinguished scientists attending, more than 90 LRF-affiliated scientists presented at the 2022 ASH Annual Meeting.
In addition to LRF’s representation through presentations, LRF researchers contributed to 705 abstracts across all hematology and 522 lymphoma-related abstracts. Eighty percent of LRF scholars — participants in LRF’s Lymphoma Scientific Research Mentoring Program (LSRMP) – authored at least one abstract at ASH.
Highlights from ASH 2022:
- Short-course Brentuximab Vedotin with Chemotherapy is Highly Active in Early-Stage Bulky Hodgkin Lymphoma
- Quality of Life Improves Quickly in Survivors of Aggressive Lymphomas
- Durable Responses Observed with Mosunetuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
- Next-Generation BTKi Zanubrutinib Demonstrates Improved Efficacy and Tolerability Compared with Ibrutinib
- Updated Index Improves Prognostication for Survival in Advanced-Stage Hodgkin Lymphoma
- Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
- Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy
- High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Plus Venetoclax
Webinar: Updates from the 2022 American Society of Hematology Annual Meeting
Learn more about pivotal lymphoma research presented at the 2022 American Society of Hematology (ASH) Annual Meeting from Laurie Sehn, MD, MPH and Pierluigi Porcu, MD.